19:41 , Nov 11, 2016 |  BC Week In Review  |  Company News

AdAlta, XL-protein deal

AdAlta and XL-protein partnered to develop and commercialize a long-acting version of AdAlta’s AD-114 to treat idiopathic pulmonary fibrosis (IPF). The partners will use XL-protein’s PASylation technology to increase the compound’s half-life and duration of...